Telix Pharmaceuticals
@TelixPharma
Telix is a biopharmaceutical company focused on developing and commercialising diagnostic and therapeutic products using targeted radiation #SeeItTreatIt
ID:809505332590309376
http://www.telixpharma.com 15-12-2016 21:08:05
820 Tweets
1,4K Followers
432 Following
Follow People
Telix has 'gone grey' for Brain Tumour Awareness Month, to highlight the challenges faced by patients and the important work that is being done to overcome these.
Learn more about Telix's brain cancer program here: telixpharma.com/brain
#BTAM Brain Tumour Alliance Australia Cure Brain Cancer
Thank you for joining Telix at #ANZSNM2024 in Christchurch, NZ
As the premier event for nuclear medicine in Australia and NZ we were pleased to have Telix’s investigational therapeutic and diagnostic assets featured in presentations across the weekend
youtu.be/VvDf8FsQkNc
Telix is live at #ANZSNM2024 in Christchurch, New Zealand!
Come and meet the team at booths #29 & #30 to learn about our extensive theranostic pipeline and opportunities for collaboration.
More on our presence here: telixpharma.com/news-views/tel…
Telix is supporting the Nurses Workshop at #ANZSNM2024 in collaboration with PCFA, NeuroEndocrine Cancer Australia & Peter Mac Cancer Centre
Topics include understanding the tumour microenvironment, dealing with side effects, and managing difficult conversations.
More on our website: bit.ly/4b4cUF8
Telix's investigational theranostic program for neuro-oncology will be showcased at the Nuclear Medicine and Neurooncology (NMN) in Vienna this week.
Nelleke Tolboom and Josef Pichler, KOLs in glioma, will present TLX101 (131I-IPA) therapy and TLX101-CDx (18F-FET) imaging.
More: nmn-society.org
Join Telix at #ANZSNM2024 this week in Christchurch, NZ.
Our theranostic programs are featured in 5 oral abstract presentations, and we're pleased to host a Breakfast Session and once again support the Nurses Workshop.
More about Telix at ANZSNM here: bit.ly/4b4cUF8
Join our breakfast at #ANZSNM2024 in Christchurch!
Explore theranostic topics including radio antibody-drug conjugates and mobile PSMA-PET/CT in prostate cancer, kidney cancer diagnosis and treatment with radiolabelled girentuximab, and AI.
Register: bit.ly/49EgmVZ